机译:抗体持续18-20个月的年龄和安全和免疫原性的增强剂量,组合DTAP-IPV // PRP〜T疫苗与在初级接种健康婴儿后的单独疫苗(DTAP,PRP〜T和IPV)相比 中华人民共和国。
Guanxi Autonomous Region Center for Disease Prevention and Control China;
National Institute for the Control of Pharmaceutical and Biological Products China;
Ping Le County Center for Disease Prevention and Control Guangxi China;
Li Pu County Center for Disease Prevention and Control Guangxi China;
Yang Shuo County Center for Disease Prevention and Control Guangxi China;
Gui Lin City Center for Disease Prevention and Control Guangxi China;
Sanofi Pasteur China;
Global Medical Affairs Sanofi Pasteur 2 avenue Pont Pasteur 69007 Lyon France;
Guanxi Autonomous Region Center for Disease Prevention and Control China;
National Institute for the Control of Pharmaceutical and Biological Products China;
Ping Le County Center for Disease Prevention and Control Guangxi China;
Li Pu County Center for Disease Prevention and Control Guangxi China;
Yang Shuo County Center for Disease Prevention and Control Guangxi China;
Gui Lin City Center for Disease Prevention and Control Guangxi China;
Sanofi Pasteur China;
Global Medical Affairs Sanofi Pasteur 2 avenue Pont Pasteur 69007 Lyon France;
Yang Shuo County Center for Disease Prevention and Control Guangxi China;
Gui Lin City Center for Disease Prevention and Control Guangxi China;
Sanofi Pasteur China;
Pentavalent vaccine; Booster; China; Pediatric; Immunogenicity; Safety;
机译:抗体持续18-20个月的年龄和安全和免疫原性的增强剂量,组合DTAP-IPV // PRP〜T疫苗与在初级接种健康婴儿后的单独疫苗(DTAP,PRP〜T和IPV)相比 中华人民共和国。
机译:将DTaP-IPV联合疫苗与单独的DTaP和IPV疫苗相比,对4-6岁的健康儿童进行学龄前加强剂量和第二剂MMR疫苗的免疫原性和安全性
机译:将DTaP-IPV联合疫苗与单独的DTaP和IPV疫苗相比,对4-6岁的健康儿童进行学龄前加强剂量和第二剂MMR疫苗的免疫原性和安全性
机译:DTaP-IPV // Hib联合疫苗与单独DTaP-IPV和Hib(PRP〜T)疫苗相比的免疫原性和安全性:韩国婴儿的随机临床试验。
机译:新型DTaP–IPV–Hep B–PRP-T联合疫苗与许可的DTaP–IPV–Hep B // PRP-T对照疫苗的免疫原性和安全性研究,均与7价肺炎球菌结合疫苗一起在2,泰国婴儿的4个月和6个月大